General discussion, page-20242

Hey Panda,

Just wanted to highlight how the market often leans towards drugs with a better safety profile, even when similar treatments are available. A few examples:

Esomeprazole (Nexium) overtook Omeprazole (Prilosec) due to its more consistent acid control and fewer side effects.

SSRIs like Prozac replaced Tricyclic Antidepressants (TCAs) because they were safer and easier to tolerate with fewer severe side effects.

DOACs like Eliquis and Xarelto became preferred over Warfarin due to their ease of use, fewer interactions, and a reduced risk of bleeding.

Second-Generation Antihistamines like Loratadine (Claritin) replaced First-Generation Antihistamines like Diphenhydramine (Benadryl) because they offered similar efficacy without causing sedation.

Aripiprazole (Abilify) gained preference over older antipsychotics like Haloperidol because it treated conditions like schizophrenia with fewer movement-related side effects.

These examples show that IF a new drug for OSA CAN offer better safety or fewer side effects, it COULD still capture significant market share despite existing competitors. The market has a history of favoring treatments that provide not just efficacy, but also a more tolerable experience for patients.